Reduction of Inappropriate Benzodiazepine Prescriptions Among Older Adults Through Direct Patient Education: The EMPOWER Cluster Randomized Trial | Clinical Pharmacy and Pharmacology | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.204.227.34. Please contact the publisher to request reinstatement.
1.
Oshima Lee  E, Emanuel  EJ.  Shared decision making to improve care and reduce costs.  N Engl J Med. 2013;368(1):6-8.PubMedGoogle ScholarCrossref
2.
Bodenheimer  T, Lorig  K, Holman  H, Grumbach  K.  Patient self-management of chronic disease in primary care.  JAMA. 2002;288(19):2469-2475.PubMedGoogle ScholarCrossref
3.
Bardes  CL.  Defining “patient-centered medicine”.  N Engl J Med. 2012;366(9):782-783.PubMedGoogle ScholarCrossref
4.
Katz  SJ, Hawley  S.  The value of sharing treatment decision making with patients: expecting too much?  JAMA. 2013;310(15):1559-1560.PubMedGoogle Scholar
5.
Cassel  CK, Guest  JA.  Choosing wisely: helping physicians and patients make smart decisions about their care.  JAMA. 2012;307(17):1801-1802.PubMedGoogle ScholarCrossref
6.
American Geriatrics Society. Choosing Wisely website. Five things physicians and patients should question. 2013. http://www.choosingwisely.org/wp-content/uploads/2013/01/about_choosingwisely_fivethings.pdf. Accessed February 28, 2014.
7.
Tannenbaum  C, Paquette  A, Hilmer  S, Holroyd-Leduc  J, Carnahan  R.  A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs.  Drugs Aging. 2012;29(8):639-658.PubMedGoogle Scholar
8.
Woolcott  JC, Richardson  KJ, Wiens  MO,  et al.  Meta-analysis of the impact of 9 medication classes on falls in elderly persons.  Arch Intern Med. 2009;169(21):1952-1960.PubMedGoogle ScholarCrossref
9.
Zint  K, Haefeli  WE, Glynn  RJ, Mogun  H, Avorn  J, Stürmer  T.  Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults.  Pharmacoepidemiol Drug Saf. 2010;19(12):1248-1255.PubMedGoogle ScholarCrossref
10.
American Geriatrics Society 2012 Beers Criteria Update Expert Panel.  American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults.  J Am Geriatr Soc. 2012;60(4):616-631.PubMedGoogle ScholarCrossref
11.
Brekke  M, Rognstad  S, Straand  J,  et al.  Pharmacologically inappropriate prescriptions for elderly patients in general practice: how common? baseline data from The Prescription Peer Academic Detailing (Rx-PAD) study.  Scand J Prim Health Care. 2008;26(2):80-85.PubMedGoogle ScholarCrossref
12.
van der Hooft  CS, Jong  GW, Dieleman  JP,  et al.  Inappropriate drug prescribing in older adults: the updated 2002 Beers criteria—a population-based cohort study.  Br J Clin Pharmacol. 2005;60(2):137-144.PubMedGoogle ScholarCrossref
13.
Fourrier  A, Letenneur  L, Dartigues  JF, Moore  N, Bégaud  B.  Benzodiazepine use in an elderly community-dwelling population: characteristics of users and factors associated with subsequent use.  Eur J Clin Pharmacol. 2001;57(5):419-425.PubMedGoogle ScholarCrossref
14.
Préville  M, Bossé  C, Vasiliadis  HM,  et al.  Correlates of potentially inappropriate prescriptions of benzodiazepines among older adults: results from the ESA study.  Can J Aging. 2012;31(3):313-322.PubMedGoogle ScholarCrossref
15.
Gallagher  HC.  Addressing the issue of chronic, inappropriate benzodiazepine use: how can pharmacists play a role?  Pharmacy. 2013;1(2):65-93.Google ScholarCrossref
16.
Parr  JM, Kavanagh  DJ, Young  RM, McCafferty  K.  Views of general practitioners and benzodiazepine users on benzodiazepines: a qualitative analysis.  Soc Sci Med. 2006;62(5):1237-1249.PubMedGoogle ScholarCrossref
17.
Srisurapanont  M, Garner  P, Critchley  J, Wongpakaran  N.  Benzodiazepine prescribing behaviour and attitudes: a survey among general practitioners practicing in northern Thailand.  BMC Fam Pract. 2005;6:27.PubMedGoogle ScholarCrossref
18.
Cook  JM, Marshall  R, Masci  C, Coyne  JC.  Physicians’ perspectives on prescribing benzodiazepines for older adults: a qualitative study.  J Gen Intern Med. 2007;22(3):303-307.PubMedGoogle ScholarCrossref
19.
Tamblyn  R, Eguale  T, Buckeridge  DL,  et al.  The effectiveness of a new generation of computerized drug alerts in reducing the risk of injury from drug side effects: a cluster randomized trial.  J Am Med Inform Assoc. 2012;19(4):635-643.PubMedGoogle ScholarCrossref
20.
Martin  P, Tamblyn  R, Ahmed  S, Tannenbaum  C.  A drug education tool developed for older adults changes knowledge, beliefs and risk perceptions about inappropriate benzodiazepine prescriptions in the elderly.  Patient Educ Couns. 2013;92(1):81-87.PubMedGoogle ScholarCrossref
21.
Donohue  JM, Cevasco  M, Rosenthal  MB.  A decade of direct-to-consumer advertising of prescription drugs.  N Engl J Med. 2007;357(7):673-681.PubMedGoogle ScholarCrossref
22.
Greene  JA, Choudhry  NK, Kesselheim  AS, Brennan  TA, Shrank  W.  Changes in direct-to-consumer pharmaceutical advertising following shifts from prescription-only to over-the-counter status.  JAMA. 2012;308(10):973-975.PubMedGoogle ScholarCrossref
23.
 Patient empowerment—who empowers whom?  Lancet. 2012;379(9827):1677.PubMedGoogle ScholarCrossref
24.
Martin  P, Tamblyn  R, Ahmed  S, Tannenbaum  C.  An educational intervention to reduce the use of potentially inappropriate medications among older adults (EMPOWER study): protocol for a cluster randomized trial.  Trials. 2013;14:80.PubMedGoogle ScholarCrossref
25.
Nasreddine  ZS, Phillips  NA, Bédirian  V,  et al.  The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.  J Am Geriatr Soc. 2005;53(4):695-699.PubMedGoogle ScholarCrossref
26.
Pachana  NA, Byrne  GJ, Siddle  H, Koloski  N, Harley  E, Arnold  E.  Development and validation of the Geriatric Anxiety Inventory.  Int Psychogeriatr. 2007;19(1):103-114.PubMedGoogle ScholarCrossref
27.
Stewart  R, Niessen  WJ, Broer  J, Snijders  TA, Haaijer-Ruskamp  FM, Meyboom-De Jong  B.  General Practitioners reduced benzodiazepine prescriptions in an intervention study: a multilevel application.  J Clin Epidemiol. 2007;60(10):1076-1084.PubMedGoogle ScholarCrossref
28.
Gorgels  WJ, Oude Voshaar  RC, Mol  AJ,  et al.  Discontinuation of long-term benzodiazepine use by sending a letter to users in family practice: a prospective controlled intervention study.  Drug Alcohol Depend. 2005;78(1):49-56.PubMedGoogle ScholarCrossref
29.
Holden  JD, Hughes  IM, Tree  A.  Benzodiazepine prescribing and withdrawal for 3234 patients in 15 general practices.  Fam Pract. 1994;11(4):358-362.PubMedGoogle ScholarCrossref
30.
Bashir  K, King  M, Ashworth  M.  Controlled evaluation of brief intervention by general practitioners to reduce chronic use of benzodiazepines.  Br J Gen Pract. 1994;44(386):408-412.PubMedGoogle Scholar
31.
Kaur  S, Mitchell  G, Vitetta  L, Roberts  MS.  Interventions that can reduce inappropriate prescribing in the elderly: a systematic review.  Drugs Aging. 2009;26(12):1013-1028.PubMedGoogle ScholarCrossref
32.
Patterson  SM, Hughes  C, Kerse  N, Cardwell  CR, Bradley  MC.  Interventions to improve the appropriate use of polypharmacy for older people.  Cochrane Database Syst Rev. 2012;5:CD008165.PubMedGoogle Scholar
33.
Monane  M, Matthias  DM, Nagle  BA, Kelly  MA.  Improving prescribing patterns for the elderly through an online drug utilization review intervention: a system linking the physician, pharmacist, and computer.  JAMA. 1998;280(14):1249-1252.PubMedGoogle ScholarCrossref
34.
Eldridge  SM, Ashby  D, Kerry  S.  Sample size for cluster randomized trials: effect of coefficient of variation of cluster size and analysis method.  Int J Epidemiol. 2006;35(5):1292-1300.PubMedGoogle ScholarCrossref
35.
Ukoumunne  OC, Forbes  AB, Carlin  JB, Gulliford  MC.  Comparison of the risk difference, risk ratio and odds ratio scales for quantifying the unadjusted intervention effect in cluster randomized trials.  Stat Med. 2008;27(25):5143-5155.PubMedGoogle ScholarCrossref
36.
McAlister  FA, Straus  SE, Guyatt  GH, Haynes  RB; Evidence-Based Medicine Working Group.  Users’ guides to the medical literature, XX: integrating research evidence with the care of the individual patient.  JAMA. 2000;283(21):2829-2836.PubMedGoogle ScholarCrossref
37.
Salzman  C.  Clinical Geriatric Psychopharmacology. Baltimore, MD: Lippincott Williams & Wilkins; 1998.
38.
Pimlott  NJ, Hux  JE, Wilson  LM, Kahan  M, Li  C, Rosser  WW.  Educating physicians to reduce benzodiazepine use by elderly patients: a randomized controlled trial.  CMAJ. 2003;168(7):835-839.PubMedGoogle Scholar
39.
Ten Wolde  GB, Dijkstra  A, van Empelen  P, van den Hout  W, Neven  AK, Zitman  F.  Long-term effectiveness of computer-generated tailored patient education on benzodiazepines: a randomized controlled trial.  Addiction. 2008;103(4):662-670.PubMedGoogle ScholarCrossref
40.
Ten Wolde  GB, Dijkstra  A, Van Empelen  P, Neven  AK, Zitman  FG.  Social-cognitive predictors of intended and actual benzodiazepine cessation among chronic benzodiazepine users.  Addict Behav. 2008;33(9):1091-1103.PubMedGoogle ScholarCrossref
41.
Gorgels  WJ, Oude Voshaar  RC, Mol  AJ,  et al.  Predictors of discontinuation of benzodiazepine prescription after sending a letter to long-term benzodiazepine users in family practice.  Fam Pract. 2006;23(1):65-72.PubMedGoogle ScholarCrossref
42.
Bain  KT, Holmes  HM, Beers  MH, Maio  V, Handler  SM, Pauker  SG.  Discontinuing medications: a novel approach for revising the prescribing stage of the medication-use process.  J Am Geriatr Soc. 2008;56(10):1946-1952.PubMedGoogle ScholarCrossref
43.
Parr  JM, Kavanagh  DJ, Cahill  L, Mitchell  G, McD Young  R.  Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta-analysis.  Addiction. 2009;104(1):13-24.PubMedGoogle ScholarCrossref
44.
Voshaar  RC, Couvée  JE, van Balkom  AJ, Mulder  PG, Zitman  FG.  Strategies for discontinuing long-term benzodiazepine use: meta-analysis.  Br J Psychiatry. 2006;189:213-220.PubMedGoogle ScholarCrossref
45.
Briesacher  BA, Soumerai  SB, Field  TS, Fouayzi  H, Gurwitz  JH.  Medicare part D’s exclusion of benzodiazepines and fracture risk in nursing homes.  Arch Intern Med. 2010;170(8):693-698.PubMedGoogle ScholarCrossref
46.
Tannenbaum  C, Tsuyuki  RT.  The expanding scope of pharmacists’ practice: implications for physicians.  CMAJ. 2013;185(14):1228-1232.PubMedGoogle ScholarCrossref
Original Investigation
June 2014

Reduction of Inappropriate Benzodiazepine Prescriptions Among Older Adults Through Direct Patient Education: The EMPOWER Cluster Randomized Trial

Author Affiliations
  • 1Faculty of Medicine, Université de Montréal, Montréal, Quebec, Canada
  • 2Faculty of Pharmacy, Université de Montréal, Montréal, Quebec, Canada
  • 3Department of Medicine, McGill University, Montréal, Quebec, Canada
  • 4Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montréal, Quebec, Canada
  • 5The Respiratory Epidemiology and Clinical Research Unit, McGill University Health Centre, Montréal, Quebec, Canada
  • 6Faculty of Medicine, School of Physical & Occupational Therapy, McGill University, Montréal, Quebec, Canada
JAMA Intern Med. 2014;174(6):890-898. doi:10.1001/jamainternmed.2014.949
Abstract

Importance  The American Board of Internal Medicine Foundation Choosing Wisely Campaign recommends against the use of benzodiazepine drugs for adults 65 years and older. The effect of direct patient education to catalyze collaborative care for reducing inappropriate prescriptions remains unknown.

Objective  To compare the effect of a direct-to-consumer educational intervention against usual care on benzodiazepine therapy discontinuation in community-dwelling older adults.

Design, Setting, and Participants  Cluster randomized trial (EMPOWER [Eliminating Medications Through Patient Ownership of End Results] study [2010-2012, 6-month follow-up]). Community pharmacies were randomly allocated to the intervention or control arm in nonstratified, blocked groups of 4. Participants (303 long-term users of benzodiazepine medication aged 65-95 years, recruited from 30 community pharmacies) were screened and enrolled prior to randomization: 15 pharmacies randomized to the educational intervention included 148 participants and 15 pharmacies randomized to the “wait list” control included 155 participants. Participants, physicians, pharmacists, and evaluators were blinded to outcome assessment.

Interventions  The active arm received a deprescribing patient empowerment intervention describing the risks of benzodiazepine use and a stepwise tapering protocol. The control arm received usual care.

Main Outcomes and Measures  Benzodiazepine therapy discontinuation at 6 months after randomization, ascertained by pharmacy medication renewal profiles.

Results  A total of 261 participants (86%) completed the 6-month follow-up. Of the recipients in the intervention group, 62% initiated conversation about benzodiazepine therapy cessation with a physician and/or pharmacist. At 6 months, 27% of the intervention group had discontinued benzodiazepine use compared with 5% of the control group (risk difference, 23% [95% CI, 14%-32%]; intracluster correlation, 0.008; number needed to treat, 4). Dose reduction occurred in an additional 11% (95% CI, 6%-16%). In multivariate subanalyses, age greater than 80 years, sex, duration of use, indication for use, dose, previous attempt to taper, and concomitant polypharmacy (10 drugs or more per day) did not have a significant interaction effect with benzodiazepine therapy discontinuation.

Conclusions and Relevance  Direct-to-consumer education effectively elicits shared decision making around the overuse of medications that increase the risk of harm in older adults.

Trial Registration  clinicaltrials.gov Identifier: NCT01148186

×